Abstract: The invention provides a system for monitoring a patient that includes: 1) a blood test that measures an Apo E genotype or a derivative thereof from the patient to generate Apo B information; 2) a database that receives and stores the patient's Apo E information; and 3) an Internet-based system connected to the database and configured to process the Apo E information with an algorithm that, in response, generates a diet and treatment plan for the patient.

Abstract: The disclosure relates to an interactive, web based cardiovascular healthcare management system which has an infomediary site with databases having information relating to cardiovascular disease risk factors such as age, blood pressure, LDL, HDL and subfractions thereof and cardiovascular disease management such as diet, exercise, drugs and cardiovascular education materials. The physician can communicate electronically with the infomediary site to obtain patient test results and formulate a patient treatment plan from the diet, exercise and drug data. The physician can electronically communicate treatment plans to the patient through a record in the infomediary site. The patient can electronically communicate compliance information to the physician through the patient record. The infomediary site may also provide a case manager to provide initial draft treatment plans to the physician, gather patient history data and/or patient treatment plan compliance data.

Abstract: The invention provides a data base of LDL, I, IIa, IIb, IIIa, IIb, IVa, IVb and HDL2a, HDL2b, HDL 3a, HDL 3b and HDL 3c together with patient data such as HDL-C, LDL-C, Apo A, ApoB, Lp(a) and patient personal data useful for treatment, diagnosing, and monitoring cardiovascular disease. The data base contains the LDL and HDL subfraction data in quantitative mg/dl values and permits deriving relationship amongst the LDL and HDL values and cardiovascular disease. Quantitative data permits more effective treatment and monitoring of cardiovascular disease. For example, quantitative differences in LDL and HDL subclass levels can determine the need for more or less aggressive treatment. The data base which includes patient events, procedures, interventions which is correlated to LDL and HDl quantitative subclass data permits development of personalized patient treatment plans and monitoring the effectiveness of such treatment.

Abstract: Described are polymer monolith compositions for separating high density lipoprotein, as well as related methods of use.

Abstract: This invention is directed to a data base which contains data for HDL2b, LDL IIIa & LDL IIIb and LDL IVb subclasses all in mg/Dl and which is correlated to cardiovascular disease.

Abstract: The invention provides a system for monitoring a patient that includes: 1) a blood test that measures an Apo E genotype or a derivative thereof from the patient to generate Apo B information; 2) a database that receives and stores the patient's Apo E information; and 3) an Internet-based system connected to the database and configured to process the Apo E information with an algorithm that, in response, generates a diet and treatment plan for the patient.

Abstract: The invention provides novel methods for selecting an optimal diet and exercise regimen for a patient based on the consideration of several factors, including low density lipoprotein (LDL) and high density lipoprotein (HDL) subclass levels. Furthermore, the invention provides novel methods for treating a patient with cardiovascular disease (CVD) or at risk of developing CVD through selection of an optimal diet and exercise regimen, based on the measurement of risk factors, including LDL and HDL subclass levels.

Abstract: The invention provides a method for identifying patients with normal NCEP lipid levels who are in need of treatment for cardiovascular disease comprising measuring one or more LDL or HDL particle subclass levels and identifying abnormal LDL or HDL subclass levels. LDL III a+b and HDL 2b are preferred subclasses.

Abstract: The invention provides novel methods for selecting an optimal diet and exercise regimen for a patient based on the consideration of several factors, including low density lipoprotein (LDL) and high density lipoprotein (HDL) subclass levels. Furthermore, the invention provides novel methods for treating a patient, comprising selecting an optimal diet and exercise regimen and monitoring the patient. Patients appropriate for the methods of the invention include, for example, those with cardiovascular disease (CVD) or at risk of developing CVD. In contrast to prior methods, the methods of the invention are based on the measurement of risk factors, including LDL and HDL subclass levels, that have not previously been used to select a diet and exercise regimen.

Abstract: The invention provides a method for identifying patients with normal NCEP lipid levels who are in need of treatment for cardiovascular disease comprising measuring one or more LDL or HDL particle subclass levels and identifying abnormal LDL or HDL subclass levels.

Abstract: The invention provides a method for identifying patients who will require multiple invasive cardiac procedures comprising measuring elevated LDL IVb levels in patients who have had or will have invasive heart surgery.

Abstract: The invention provides a data base of LDL, I, Ia, IIb, IIIa, IIb, IVa, IVb and HDL2a, HDL2b, HDL 3a, HDL 3b and HDL 3c together with patient data such as HDL-C, LDL-C, Apo A, ApoB, Lp(a) and patient personal data useful for treatment, diagnosing, and monitoring cardiovascular disease. The data base contains the LDL and HDL subfraction data in quantitative mg/dl values and permits deriving relationship amongst the LDL and HDL values and cardiovascular disease. Quantitative data permits more effective treatment and monitoring of cardiovascular disease. For example, quantitative differences in LDL and HDL subclass levels can determine the need for more or less aggressive treatment. The data base which includes patient events, procedures, interventions which is correlated to LDL and HD1 quantitative subclass data permits development of personalized patient treatment plans and monitoring the effectiveness of such treatment.

Abstract: The invention provides a method for identifying patients with normal NCEP lipid levels who are in need of treatment for cardiovascular disease comprising measuring one or more LDL or HDL particle subclass levels and identifying abnormal LDL or HDL subclass levels.